News

2018 March

28
/03
Oxypoint successfully raises €3.8 million in series A funding
Antwerp, March 28th, 2018 - Oxypoint nv, the award-winning University of Antwerp spin-off, bringing innovation to the medical device market for oxygen therapy in hospitals, announced today the closing of a €3.8 million Series A financing round led by the Flemish investment company PMV, together with a family office. The investment round was guided by Wouter Van Roost, who was appointed CEO of the company. The company will use the proceeds to bring its unique proprietary CE-labelled Econo-Comfort™ Oxygen Flowmeter to the European market and to further expand its product range of novel oxygen-therapy administering medical devices.

2018 January

18
/01
LindaCare raises seven million Euro funding to improve remote patient monitoring for chronic disease management
LindaCare, a digital health company specializing in remote patient monitoring solutions for chronic disease management, today announced a seven million Euro Series B investment, featuring participation by Philips, together with PMV as new investors. Existing investors Capricorn ICT Arkiv, Connecticut Innovations and a number of other minority shareholders also participated in this round.
11
/01
PharmaFluidics raises 7.3 million Euros
PharmaFluidics raises 7.3 million euro to expand commercialization of novel micro-chip device for biomarker, diagnostics and drug development applications
04
/01
Rewind Therapeutics secures 15.2 M EURO to develop novel remyelination therapies
Rewind Therapeutics, a privately held Belgian biotech company, today announced the completion of a €15.2 million Series A financing to develop novel re-myelinating therapies for patients suffering from Multiple Sclerosis and other myelin-related diseases. The round was led by life science investors Boehringer Ingelheim Venture Fund (BIVF), Merck Ventures BV (MV) and the Flemish investment company PMV, together with KU Leuven’s Centre for Drug Design and Discovery (CD3) and KU Leuven Gemma Frisius Fonds (GFF).